Ricks told CNBC Wednesday that Lilly had held off on advertising Zepbound and launching the drug internationally in order to boost inventory in the U.S.: We havent been stimulating demand the way we had originally planned. Yet on the earnings call, Ricks maintained that underlying growth for the drugs was as strong as we would have hoped. Ricks asserted that Lilly management did not view the gap between the Q3 results and the projections of even higher growth as indicating a softening of demand for the GLP-1 drugs: Demand for Mounjaro and Zepbound has been strong and continues to grow as we expand both access and supply. Johnson denied that competition from compounders had a huge financial impact on Lillys business
Although the EDE-Q provides a comprehensive profile of eating-disorder symptoms, it is relatively lengthy and more detailed than is practical for rapid routine screening, making it better suited for diagnostic evaluation or monitoring rather than brief assessment in settings where GLP-1 RAs are prescribed
Glutathione plays a vital role in supporting the immune system
Regular follow-up appointments should be scheduled according to individual needs, typically every 3-6 months during the first year of GLP-1 therapy, with thyroid function testing as clinically indicated
8 weeks 56 syringes 1 box of 100 leaves headroom for losses
Thanks to their new packaging, Holland & Barret has reduced the plastic use by almost 500 tons per year since 2022
